SEARCH HEALTH CONDITIONS BY ALPHABETS
CLN2 Disease
Medications for Neuronal Ceroid Lipofuscinosis
Other titles: Classic Late Infantile Neuronal Ceroid Lipofuscinosis; CLN2 Disease; Late-Infantile Batten Disease; Neuronal Ceroid Lipofuscinosis Type 2
Around Neuronal Ceroid Lipofuscinosis: CLN2 disease is an inherited disease brought on by a mutation on the CLN2 gene which results in a reduced activity of a lysosomal enzyme referred to as tripeptidyl peptidase 1 (TPP1). Activity of this TPP1`s effect is that proteins and lipid storage in other cells and nerves is abnormal and cells cannot work properly leading to the evolution of symptoms. Signs and symptoms of this disease usually begin between 2 yrs of age and 4 yrs of age with the very first symptom usually being seizures, progressing to issues with walking and address, and the disease progresses the patient becomes dependent on families for most their daily needs.
Drugs Used to Cure Neuronal Ceroid Lipofuscinosis
The following set of medications have been in some way related to, or utilized at the treating this condition.
| Medication name | Rx / OTC | Pregnancy | CSA | Alcohol | Reviews | Rating | Popularity |
|---|---|---|---|---|---|---|---|
| Brineura | Rx | N | Insert review | 0.0 | |||
Generic title: cerliponase alfa systemic Drug category: lysosomal enzymes For consumers: dose, side effects For professionals: AHFS DI Monograph, Prescribing Information | |||||||
| cerliponase alfa | Rx | N | Insert review | 0.0 | |||
Generic title: cerliponase alfa systemic Brand title: Brineura Drug category: lysosomal enzymes For consumers: dosage, For professionals: a z Drug Facts, AHFS DI Monograph | |||||||
Legend
| Rx | Prescription Only |
|---|---|
| OTC | On The Counter |
| Rx/OTC | Prescription or Over The Counter |
| Away Prizes | This medication might well not be approved by the FDA for the treatment of the condition. |
| Pregnancy Category | |
|---|---|
| A | Adequate and well-controlled studies have failed to present a risk to the fetus within the first trimester of pregnancy (and there is no evidence of risk in later trimesters). |
| B | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in elderly women. |
| C | Animal reproduction studies have demonstrated an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but possible benefits may warrant used in pregnant women despite potential risks. |
| D | there was positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but possible benefits may justify used in pregnant women despite potential risks. |
| X | Studies in animals or humans have demonstrated fetal abnormalities or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in used in elderly women obviously outweigh potential gains. |
| N | FDA has not classified this drug. |
| Controlled Substances Act (CSA) Program | |
|---|---|
| N | Is not at the mercy of the Controlled Substances Act. |
| 1 | includes a higher potential for misuse. Has no currently accepted medical use in treatment in the United States. There`s just a lack of accepted safety for use under medical supervision. |
| Two | includes a higher potential for misuse. Has a currently accepted medical use with severe restrictions or a currently accepted medical use in treatment in the United States. Psychotherapy can lead to acute psychological or physical dependency. |
| 3 | Has a possibility for abuse less than those in programs 1 and 2. Has a currently accepted medical use in treatment in the United States. Psychotherapy can lead to physical dependence or high psychological dependence. |
| 4 | includes a minimal potential for abuse in accordance with those in schedule 3. It has a currently accepted medical use in treatment in the United States. Psychotherapy can lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
| 5 | includes a minimal potential for abuse in accordance with those in schedule 4. Has a currently accepted medical use in treatment in the United States. Psychotherapy can lead to limited physical dependence or psychological dependence. |
| Alcohol | |
|---|---|
| X | Interacts with Medication. |
Browse Treatment Plans
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- Frazee
- S
- T
- U
- V
- W
- X
- Y
- Z
Further advice
Always seek advice from your healthcare provider to be sure the information applies to your personal circumstances.
Top USA Pharma Companies
Popular Categories
Easily find an affordable health insurance plan
